Higher meat intake in older adults may raise risk for ASCVD
Aug 05, 2022
Associations for unprocessed red meat, total meat and total ASF with atherosclerotic cardiovascular disease were mediated by trimethylamine N-oxide-related metabolites.
Xylitol linked to incident major adverse cardiovascular event risk
Jun 17, 2024
The sweetener xylitol was linked to incident major adverse cardiovascular event risk in an initial untargeted metabolomics study and was confirmed in a validation cohort.
Physical function in older adults linked to CV event risk
Aug 31, 2022
A low or intermediate score on Short Physical Performance Battery was linked to an increased risks for composite and individual CVD outcomes.
Nonphysician-implemented multifaceted intervention beneficial in HTN
Jun 20, 2024
Significant reductions were seen in total cardiovascular disease and all-cause mortality for those aged 60 years and older; significant reductions also were seen for those younger than 60 years.
Omega-3 fatty acids tied to better cardiovascular outcomes
Jul 12, 2021
Cardiovascular risk reduction was more prominent with EPA monotherapy versus EPA + DHA therapy.
Up to 30 percent of CVD mortality attributable to excess salt intake
Mar 29, 2024
The population-attributable risk estimates suggest that sodium above the recommended intake is linked to 10 to 30% of CVD mortality.
AHA: PREVENT risk calculator estimates risk for cardiovascular disease
Nov 13, 2023
PREVENT equations were developed and validated in adults aged 30 to 79 years without known CVD and included eGFR as a predictor.
FDA approves Wegovy to lower risk for CVD events in patients with obesity
Mar 08, 2024
Agency’s action could widen access to the drug if more insurance companies decide to cover it
Patterns studied for alcohol intake, outcomes in patients with CVD
Jul 29, 2021
Relative to nondrinkers, a J-shaped curve was seen for all-cause mortality, cardiovascular mortality, and cardiovascular events in drinkers with preexisting cardiovasular disease.
Menopausal hormone therapy use beyond 65 years beneficial
Apr 16, 2024
Use of menopausal hormone therapy beyond age 65 years is associated with risk reductions in mortality as well as specific cancers and cardiovascular diseases, according to a study published online April...